my personal edition > diabetes > news
E-Mail this DGNews to a colleague
DGNews
Metformin Works Well as Monotherapy in Type 2 Diabetes Especially in Overweight or Obese Patients
HOBOKEN, N.J. -- July 15, 2005 -- People with type 2 diabetes who are overweight or obese are at increased risk of cardiovascular diseases like strokes and heart attacks. Metformin can help tackle their diabetes while also protecting against diabetes-related organ damage.
In diabetes, either the body fails to produce enough insulin or the cells ignore the insulin. Without this hormonal signal working properly glucose increases in the blood stream, but still can't be used by the body. The number of people with type 2 diabetes is rising because it is linked to overweight or obesity.
Metformin increases peripheral and liver sensitivity to insulin. It therefore reduces the amount of glucose released from the liver and increases the amount taken up and used by the rest of the body. It also reduces the level of fats in blood and helps people stabilise or reduce their weight. Taken together, these help reduce damage to blood vessels throughout the body.
By looking at data contained in 29 separate trials, the Cochrane Review Authors concluded that metformin works well as a single-drug therapy for many people with type 2 diabetes. In addition to helping control diabetes, people who were overweight, had type 2 diabetics and were on intensive metformin were also less likely to be affected by stroke, heart attacks, and are less likely to die.
The authors could not compare metformin with newer drugs, because trials of more recently available drugs such as new sulphonylureas, thiazolidinediones, meglitinides and alpha glucosidase inhibitors did not show any direct comparisons with metformin for these primary outcomes.
They could, however, determine that metformin was as good as, or better than these other drugs at controlling blood glucose and lipids, and body weight.
"Our review of literature suggests that metformin is a good first line therapy for overweight or obese people with type 2 diabetes," says lead author Antonio Saenz, who works as a family physician in Madrid, Spain.
Review Title: Saenz et al: Metformin monotherapy for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 2005 Issue 3
SOURCE: Wiley & Sons Inc.
All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.
| 
